• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Does Methylphenidate Use in Children and Young Adults Increase Risk of Suicide?

Does Methylphenidate Use in Children and Young Adults Increase Risk of Suicide?

November 1, 2017
Arian Ayon Verduzco. Pharm.D candidate (2018)
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Arian Ayon Verduzco. Pharm.D candidate (2018) Ms. Verduzco has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review Of: Man KKC et al, JAMA Psychiatry 2017;74(10):1048–1055

Some studies have indicated that patients with ADHD may be at an increased risk of suicide. While these studies have shown associations between methylphenidate use and suicide, it is not clear whether the stimulant actually causes suicidality or whether patients taking stimulants are suicidal for other reasons. This study sought to directly investigate a causal association.

This retrospective population-based case series study used data from a comprehensive patient reporting system in Hong Kong. In total, 25,629 patients aged 6–25 who had taken methylphenidate between January 2001 and December 2015 were identified. Of these patients, 154 of them had attempted suicide during the 15-year study period. In order to try to determine if methylphenidate was actually causing the suicidality, researchers zeroed in on the suicide attempt rate during three periods, or “risk windows,” as they called them: the pre-exposure period (90 days), the first 90 days of methylphenidate use, and any subsequent methylphenidate use.

Here’s what they found after their analysis. The chances of a suicide attempt were highest during the 90 days before the methylphenidate prescription (6.5-fold higher than baseline), and the risk dropped a little bit during the first 90 days of methylphenidate use down to a 4-fold risk. There was essentially no elevated suicide attempt risk observed with subsequent long-term methylphenidate use.

The authors conclude that the “most parsimonious interpretation of this pattern” is that methylphenidate use does not in itself increase the risk of suicide. Instead, the decision to start methylphenidate is preceded by a period of increased suicidal ideation, which gradually drops once the methylphenidate is started.

CCPR’s Take: When patients are considering starting a stimulant, they are going through difficult times, and it’s not surprising that the risk of a suicide attempt is high. We should feel comfortable medicating such patients with stimulants to treat their ADHD symptoms without the fear that the medication itself might aggravate suicidality.
Child Psychiatry
KEYWORDS adhd child-psychiatry research_updates
    Arian Ayon Verduzco. Pharm.D candidate (2018)

    More from this author
    www.thecarlatreport.com
    Issue Date: November 1, 2017
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Adolescents, CCPR, November/December 2017
    Does Guanfacine Affect Tic Severity in Children With Chronic Tic Disorders?
    Does Methylphenidate Use in Children and Young Adults Increase Risk of Suicide?
    Tips on Managing Medications With Adolescents
    Understanding Risk-Taking in Adolescents
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.